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Simple Summary: Candidate endophenotypes should be systematically assessed against five criteria:
(i) the endophenotype is associated with disease in the population; (ii) the endophenotype is heritable;
(iii) within families, endophenotype and disease co-segregate; (iv) the endophenotype found in
affected family members is found in non-affected family members at a higher rate than in the general
population and (v) the endophenotype is primarily state independent (manifests in an individual
whether or not disease is active). This study assesses the suitability of mammographic breast density
as an endophenotype for breast cancer. Formally establishing a trait as a disease endophenotype
confirms that the trait and endophenotype share a biological basis, thereby enabling genetic dissection
of an endophenotype to inform disease risk. As breast density can be measured for any woman who
has had a mammogram, studies investigating the genetic architecture of breast density could identify
breast cancer risk variants that act through effects on this trait.
Abstract: Mammographic breast density (MBD) is a strong and highly heritable predictor of breast
cancer risk and a biomarker for the disease. This study systematically assesses MBD as an endopheno-
type for breast cancer—a quantitative trait that is heritable and genetically correlated with disease risk.
Using data from the family-based kConFab Study and the 1994/1995 cross-sectional Busselton Health
Study, participants were divided into three status groups—cases, relatives of cases and controls.
Participant’s mammograms were used to measure absolute dense area (DA) and percentage dense
area (PDA). To address each endophenotype criterion, linear mixed models and heritability analysis
were conducted. Both measures of MBD were significantly associated with breast cancer risk in two
independent samples. These measures were also highly heritable. Meta-analyses of both studies
showed that MBD measures were higher in cases compared to relatives (β = 0.48, 95% CI = 0.10, 0.86
and β = 0.41, 95% CI = 0.06, 0.78 for DA and PDA, respectively) and in relatives compared to controls
(β = 0.16, 95% CI = −0.24, 0.56 and β = 0.16, 95% CI = −0.21, 0.53 for DA and PDA, respectively).
This study formally demonstrates, for the first time, that MBD is an endophenotype for breast cancer.
Keywords: mammographic breast density; breast cancer; risk factor; endophenotype
1. Introduction
Breast cancer is the second most commonly diagnosed cancer in Australia and the most
commonly diagnosed cancer in females, with a lifetime prevalence of 1 in 7 [1]. Women
with an affected first-degree female relative are at approximately two-fold greater risk of
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developing breast cancer than women from the general population. Rare, highly penetrant
mutations in genes such as BRCA1/2, identified by linkage/positional cloning in breast can-
cer families more than 20 years ago, remain the single largest known genetic risk factor for
breast cancer, accounting for ~30% of excess familial risk [2]. In recent years, large genome-
wide association studies (GWAS) in unrelated individuals have identified many common,
low-risk alleles that together account for an additional ~18% of familial risk [3]. New study
designs are needed to identify the remaining “missing heritability” and causal risk variants
that also contribute to inter-individual differences in breast cancer susceptibility.
Mammographic breast density (MBD) is a strong [4,5] and highly heritable [6,7]
predictor of breast cancer risk and considered a strong biomarker for the disease. MBD
is the white appearance of epithelial and stromal tissue on a mammogram, in contrast to
adipose (fatty) breast tissue which appears dark. Dense breast tissue is quite common,
with ~43% of screen-aged women estimated to have heterogeneously or extremely dense
breasts [8]. MBD is a modifiable risk factor [9] and it has been shown that reducing MBD
by medical interventions such as tamoxifen is associated with significantly reduced breast
cancer risk [10]. Previous investigations of the associations between known common
breast cancer-susceptibility variants and MBD has demonstrated significant evidence of a
shared genetic basis between MBD and breast cancer risk with ~18% overlap of genetic
associations [11]. However, MBD has never been formally examined as an endophenotype
for breast cancer—a quantitative trait that is heritable and genetically correlated with
disease risk. Formally establishing a trait as a disease endophenotype confirms that the
trait and endophenotype share a biological basis, thereby enabling genetic dissection of an
endophenotype to inform disease risk. As MBD can be measured for any woman who has
had a mammogram, study designs that quantitatively examine the genetic architecture of
MBD could significantly help identify risk variants for breast cancer that act through effects
on this trait. As MBD is a modifiable risk factor, analysis of the genetic overlap could also
help identify other possible less-invasive interventions that could be used to target women
at high risk of breast cancer and thereby aid prevention of the disease.
Candidate endophenotypes should be systematically assessed against five endopheno-
type criteria: [12] (i) the endophenotype is associated with disease in the population; (ii) the
endophenotype is heritable; (iii) within families, endophenotype and disease co-segregate;
(iv) the endophenotype found in affected family members is found in non-affected family
members at a higher rate than in the general population and (v) the endophenotype is
primarily state independent (manifests in an individual whether or not illness is active).
This study aims to assess the suitability of MBD measures as endophenotypes for
breast cancer. As it is accepted that MBD is state independent of breast cancer (i.e., breasts
can be dense both with and without the presence of breast cancer) [13], we investigate the
suitability of MBD against the remaining four endophenotype criteria using supporting
data from two epidemiological studies—the kConFab Consortium and the Busselton
Health Study.
2. Materials and Methods
2.1. Study Participants
Two study populations were used to assess the suitability of mammographic den-
sity measures as endophenotypes for breast cancer—kConFab and the Busselton Health
Study (BHS).
2.1.1. kConFab
kConFab (The Kathleen Cuningham Foundation Consortium for research into Familial
Breast cancer) has been collecting genetic, epidemiological, medical and psychosocial data
from families with a strong history of breast cancer since 1997 and has accumulated data on
more than 1400 multigenerational, multicase kindreds [14]. The consortium makes data and
biospecimens widely available to researchers for use in peer-reviewed, ethically-approved
research. Methods for participant recruitment and data collection are described in detail
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elsewhere [14]. Via the Western Australian Department of Health Data Linkage Branch, we
linked all kConFab participants residing in Western Australia (WA) with BreastScreen WA
to obtain and measure their mammographic images. This was possible for 426 Western
Australian kConFab participants from 197 families with more than 200 cases of breast
cancer. For the current study, we selected families who were known not to carry the
BRCA1/2 genes and who had members with available mammograms from Breast Screen
Western Australia (n = 405 participants from 183 families (plus friends) with 114 cancers).
Ethics approval was obtained from the Western Australian Department of Health
Human Research Ethics Committee (#RGS0000002834) and the University of Western
Australia Human Research Ethics Office (#RA/4/1/9183).
2.1.2. Busselton Health Study (BHS)
Busselton is a rural, historically stable community ~230 km south of Perth, WA;
predominantly of British (Anglo-Saxon) expatriate origin. The BHS is one of the longest-
running international epidemiological research programs, with repeated cross-sectional
surveys of adults undertaken between 1966 and 2007. The recruitment and data collection
of participants from the BHS have previously been described in detail [15]. In 1994/1995, a
follow-up survey was conducted of all surviving participants previously surveyed with
approximately 5700 individuals attending. High-density single-nucleotide polymorphism
(SNP) genotyping data are available for 4671 of these 1994/1995 BHS participants using
either an Illumina 660 W or 610 W genome-wide association chip [16]. Other available
data include obesity-related markers (measured at time of appointment by a research
nurse), reproductive history, and exogenous hormone use. Via the Western Australian
Department of Health Data Linkage Branch, we linked all 1994/1995 BHS participants
with BreastScreen WA to obtain and measure their mammographic images, and the WA
Cancer Registry to obtain all breast cancer diagnoses from 1980 onwards.
Informed consent was granted from all participants in the 1994/1995 survey and ethics
was obtained by the University of Western Australia Human Research Ethics Committee
(#RA4/1/6694). The current study was approved by the Western Australian Department
of Health Human Research Ethics Committee (#RGS0000002801).
2.2. Status Allocation
The participants for both studies were divided into three status groups: cases, unaf-
fected relatives of cases (henceforward relatives) and controls. For the kConFab participants,
information collected about each participant’s families was used to create pedigrees and
assign each participant to a status group. For BHS participants, allocation to a status group
was determined using the genetic relatedness matrix (GRM) generated from genome-wide
SNP genotype data. BHS participants were assigned either as a case if they had a WA
Cancer Registry-confirmed breast cancer, as a relative if they were not a case and the GRM
estimated them to have a relatedness of greater than 0.0875 to a case (i.e., proportion of
relatedness to a case to capture 1st cousins or greater, where relatedness of 0.125 indicates
third-degree relatives and 0.5 indicates first-degree relatives), or finally as a control if
they were not related to a case and were not a case themselves [17]. Within both studies,
all relatives were breast cancer free and if a case was related to another case, they were
assigned to the case group; however, their relationship to the case was captured through
the inclusion of the genetic relatedness matrix in all analyses.
2.3. Mammogram Selection
Cranio-caudal film mammograms were retrieved from BreastScreen WA, digitized
and measured by author JS using the Cumulus software (Sunnybrook Health Sciences
Centre, Toronto, ON, Canada). Where mammograms from multiple screening visits were
available, the pre-diagnosis mammogram closest to the diagnosis date was selected for
cases. For relatives and controls, the mammogram closest to the epidemiological data
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collection date was selected. If a relative or control had no epidemiological data, the earliest
mammogram available was selected.
The MBD measurements included absolute dense area and percentage dense area.
Percentage dense area could not be measured for six participant’s mammograms from
the kConFab study as the images had bad edges and thus total breast size could not be
measured. Mammograms were measured twice for 10% of participants to assess reliability.
Intraclass correlation coefficients for absolute dense area and percentage dense area were
0.98 in the kConFab Study and 0.99 in the BHS.
2.4. Data Analysis
Analyses were conducted in R version 3.6.3 [18] and Genome-wide Complex Trait
(GCTA) [19]. Medians and interquartile ranges (IQR) were used to describe the study
populations. Participants missing body mass index (BMI) information were excluded
from analyses. Descriptive analyses showed those missing BMI were similarly aged at
the time of their mammogram but were less dense than those who had reported BMI.
The GRMs were estimated using the pedigrees deduced from the family relationship
data collected during interviews for kConFab and from results of the genome-wide SNP
data for BHS. The latter was estimated using Linkage Disequilibrium Adjusted Kinships
(LDAK) software [20] as described previously [16] Relatedness was set to zero for those
with relatedness below 0.05 in the BHS GRM as this has been shown to reduce potential
bias in heritability and genetic correlation estimates from using both closely and distantly
related individuals [21]. All regression analyses were adjusted for age at mammogram,
BMI, time between mammogram and when BMI was reported, and the GRM. In addition,
all BHS analyses included number of live births and a menopause status variable (defined
as 1 if the woman had reported her periods had stopped and was not taking hormone
replacement therapy, and 0 otherwise).
2.4.1. Test of Criterion (i)—The Endophenotype Is Associated with Illness in
the Population
We assessed the association of absolute dense area and percentage breast density
with breast cancer by testing for differences between cases and combined relatives and
controls. Generalised linear mixed models, with a binomial distribution with logit link
function (R package GMMAT [22]) was used to compare the status groups adjusting for
age at mammogram, BMI, time between mammogram and BMI collection (plus number
of live births and menopause status for BHS), and the GRM as a random effect, using
Wald tests. For some models, adjustment for the GRM resulted in the variance estimate
being on the boundary of the parameter space observed. After additional testing involving
the removal of highly influential observations we determined that the estimates change
minimally when the GRM was removed and so have reported the model estimates which
do not adjust for the GRM.
2.4.2. Test of Criterion (ii)—The Endophenotype Is Heritable
Narrow-sense heritability is the proportion of the variability of the phenotype that can
be attributed to additive genetic variation. Heritability estimation for absolute dense area
(hDA) and percentage dense area (hPDA) was performed using restricted maximum likeli-
hood analysis using Genome-wide Complex Trait Analysis (GCTA) software [19]. Square
root transformations were used for both MBD measurements to normalise distributions
and analyses were adjusted for age at mammogram, BMI, time between mammogram and
BMI collection, and the GRM plus number of live births and menopause status for BHS.
2.4.3. Test of Criteria (iii)—Within Families, Endophenotype and Illness Co-Segregate and
(iv)—The Endophenotype Found in Affected Family Members Is Found in Non-Affected
Family Members at a Higher Rate than in the General Population
Linear mixed models and estimated marginal means were used to assess whether
the density measures differed across the three status groups: cases, relatives and controls.
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This is akin to testing genetic correlation, and in the presence of non-traditional family
structures within these samples, comparisons of means between the three status groups
was considered the most statistically powerful method to assess this. A square root
transformation was applied to the MBD measures to normalise the distributions and
models were adjusted for age at mammogram, BMI, time between mammogram and BMI
collection, and the GRM, plus number of live births and menopause status for BHS. As
before, estimates on the boundary space were assessed and are presented without GRM
adjustment. A meta-analysis of the results from both studies was conducted using the R
library ‘meta’.
3. Results
The final number of participants within the kConFab study was 323 (88 cases, 179 rel-
atives and 56 controls) and 1587 (92 cases, 72 relatives and 1423 controls) for the BHS.
Descriptive statistics are shown in Table 1. For both study populations, the median age for
cases was higher than in controls and relatives. BMI was similar across the groups with
relatives having slightly lower median BMIs when compared to cases and controls for both
studies. The mean relatedness of the relatives was 0.33 within the kConFab study, and 0.35
within the BHS, with approximately half of relatives in both studies either sister pairs or
mother/daughter pairs.
Table 1. Population characteristics for the two studies kConFab and BHS.
kConFab BHS
Characteristic Total(n = 323)
Controls












(n = 72, 4.5%)
Cases
(n = 92, 5.8%)
Median age (years) at
mammogram (IQR) 51.0 (13.0) 51.0 (8.5) 50.0 (14.5) 56.0 (12.3) 52.6 (15.9) 52.8 (15.7) 49.5 (11.9) 54.0 (16.9)
Median BMI at





−1084 (2644) −2990 (3452) −658 (2316) −1200 (2230) 305 (3282) 331 (3278) 1043 (3371) 24.5 (2207)
Median dense area
cm2 (IQR) 17.6 (26.3) 15.2 (28.6) 15.4 (25.3) 22.0 (26.3) 15.3 (24.4) 14.7 (23.8) 22.0 (28.6) 19.7 (24.1)
Median percentage
dense area b % (IQR)
16.6 (26.1) 16.8 (33.8) 14.8 (24.4) 20.9 (25.8) 15.0 (28.0) 14.0 (27.5) 23.0 (32.5) 19.0 (26.0)
a Negative values denote BMI was taken after mammogram. b A total of six missing from relatives of cases in kConFab due to poor
mammogram quality. Abbreviations: BHS: Busselton Health Study, BMI: body mass index, IQR: interquartile range.
3.1. Test of Criterion (i)—MBD Is Significantly Associated with Breast Cancer
Table 2 shows the associations between the MBD measures and breast cancer risk for
both the kConFab and BHS studies. Within the kConFab study, an increase in dense area
of 1 cm2 was associated with an increased odds of breast cancer of 1.015 (95% CI = 1.002,
1.029), compared to women with no breast cancer (relatives and controls). A smaller effect
size (OR = 1.009; 95% CI = 0.998, 1.019) was observed within the BHS. Similarly, an increase
of 1% in percent dense area was associated with an increased odds of breast cancer within
kConFab (OR = 1.019, 95% CI = 1.002, 1.037), with a smaller increase in the BHS (OR = 1.011,
95% CI = 0.998, 1.025).
Table 3 shows the linear regression estimates of the association between MBD measures
and case-relative-control status for both kConFab and BHS studies. Within the kConFab
study, cases had higher absolute dense area (β = 6.93, 95% CI = 0.174, 13.68) and percentage
dense area (β = 0.818, 95% CI = 0.177, 1.46) than controls. Similarly, within the BHS, cases
also had higher absolute dense area (β = 0.429, 95% CI = 0.009, 0.850) and percentage dense
area (β = 0.391, 95% CI = 0.007, 0.790). When compared to controls, however, the effect
sizes were slightly smaller. These higher MBD measure estimates among cases compared
to controls remained after meta-analysing both studies results.
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Table 2. Logistic regression estimates (odds ratios (OR) and 95% confidence intervals (CI)) showing the associations between
MBD measures and breast cancer risk for both the kConFab and BHS studies.
kConFab 1 BHS 2
Cases (n = 88)/
Relatives + Controls
(n = 235 3)
Cases (n = 88)/
Relatives (n = 179 3)
Cases (n = 88)/
Controls (n = 56)
Cases (n = 92)/
Relatives + Controls
(n = 1495)
Cases (n = 92)/
Relatives (n = 72)
Cases (n = 92)/




































































1 kConFab models adjusted for age, BMI, time between BMI measurement and mammogram and the GRM. 2 BHS models adjusted for age,
BMI and time between BMI measurement and mammogram, number of live births and menopause status. Additionally adjustment for
the GRM resulted in the variance estimate being on the boundary of the parameter space observed. After additional testing conducted
involving removal of highly influential observations we determined that the estimates change minimally when the GRM is removed and so
have reported the models which do not adjust for the GRM. 3 6 relatives are missing percentage dense area measurements due to poor
mammogram quality. 4 p value calculated using Wald test. Abbreviations: BHS: Busselton Health Study, BMI: body mass index, OR: odds
ratio, and CI: confidence interval.
Table 3. Linear regression estimates (β) of the associations between the MBD measures and case-relative-control status.
βcases vs. relatives (CI) βcases vs. controls (CI) βrelatives vs. controls (CI)
kConFab
Dense area (cm2) 0.649 (0.165, 1.13) 6.93 (0.174, 13.68) 1 0.253 (−0.404, 0.909)
Percentage dense area (%) 0.593 (0.155, 1.03) 0.818 (0.177, 1.46) 0.106 (−0.503, 0.716)
BHS
Dense area (cm2) 0.197 (−0.428, 0.822 0.429 (0.009, 0.850) 0.106 (−0.394, 0.605)
Percentage dense area (%) 0.186 (−0.508, 0.685) 0.391 (−0.007, 0.790) 0.201 (−0.269, 0.672)
Meta-analysed 2
Dense area (cm2) 0.478 (0.098, 0.859) 0.596 (0.240, 0.951) 0.161 (−0.236, 0.556)
Percentage dense area (%) 0.413 (0.060, 0.7767) 0.511 (0.173, 0.848) 0.162 (−0.210, 0.534)
Bold type indicates statistical significance at α < 0.05. Dense area and percentage dense area were square root transformed and all models
were adjusted for age, BMI, time between BMI measurement and mammogram and the GRM unless otherwise stated. In addition, BHS
models included adjustment for number of live births and menopause status. 1 The variance estimate was on the boundary of the parameter
space observed so was unable to fit model with square root transformed outcome which included the GRM. This is the effect estimate with
dense area not transformed. The effect estimate with dense area square root transformed and no GRM included is: 1.022 (0.327, 1.717)
(SE: 0.351). 2 Meta analysis results presented are from a fixed effect meta analysis (all tests of heterogeneity p > 0.10). Abbreviations: BHS:
Busselton Health Study, BMI: body mass index, and CI: confidence interval.
3.2. Test of Criterion (ii)—MBD Is Heritable
The estimated heritability of absolute dense area and percentage dense area were both sig-
nificant in both studies and were higher in kConFab (hDA = 0.587, pDA = 0.002; hPDA = 0.658,
pPDA = 0.005) than BHS (hDA = 0.398, pDA < 0.001; hPDA = 0.312, pPDA < 0.001).
3.3. Test of Criterion (iii)—Within Families, Endophenotype and Illness Co-Segregate and
(iv)—The Endophenotype Found in Affected Family Members Is Found in Non-Affected Family
Members at a Higher Rate than in the General Population
From Table 3, within the kConFab study, absolute dense area (β = 0.649, 95% CI = 0.165,
1.13) and percentage dense area (β = 0.593, 95% CI = 0.155, 1.03) were higher among cases
than relatives. Results from the BHS showed a similar pattern. However, evidence was
weaker for both absolute dense area (β = 0.197, 95% CI = −0.428, 0.822) and percentage
dense area (β = 0.186, 95% CI = −0.508, 0.685). Meta-analyses of the results from two
studies found some evidence of higher absolute dense area (β = 0.478, 95% CI = 0.098,
0.859) and percentage dense area (β = 0.413, 95% CI = 0.060, 0.777) among cases when
compared to relatives.
For both studies, less evidence was seen for higher MBD measures among relatives
compared to controls. The meta-analysis of both study results found slightly higher
absolute dense area (β = 0.161, 95% CI = −0.236, 0.556) and percentage dense area (β = 0.162,
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95% CI = −0.210, 0.534) among relatives compared to controls. However, the evidence
was weak.
Figures 1 and 2 show the estimated marginal means for case-relative-control status
for each MBD measure across both studies. The estimated marginal mean of each MBD
measure increases as the status changes from control to relative to case in both studies.
However, the confidence intervals are overlapping.
Cancers 2021, 13, x FOR PEER REVIEW 7 of 11 
 
0.002; ℎ = 0.658, 𝑝 = 0.005 ) than BHS ( ℎ = 0.398, 𝑝 < 0.001; ℎ =0.312, 𝑝 < 0.001). 
3.3. Test of Criterion (iii)—Within Families, Endophenotype and Illness Co-Segregate and (iv)—
The Endophenotype Found in Affected Family Members Is Found in Non-Affected Family 
Members at a Higher Rate Than in the General Population 
From Table 3, within the kConFab study, absolute dense area (β = 0.649, 95% CI = 
0.165, 1.13) and percentage dense area (β = 0.593, 95% CI = 0.155, 1.03) were higher among 
cases than relatives. Results from the BHS showed a similar pattern. However, evidence 
was weaker for both absolute dense area (β = 0.197, 95% CI = −0.428, 0.822) and percentage 
dense area (β = 0.186, 95% CI = −0.508, 0.685). Meta-analyses of the results from two studies 
found some evidence of higher absolute dense area (β = 0.478, 95% CI = 0.098, 0.859) and 
percentage dense area (β = 0.413, 95% CI = 0.060, 0.777) among cases when compared to 
relatives. 
For both studies, less evidence was seen for higher MBD measures among relatives 
compared to controls. The meta-analysis of both study results found slightly higher abso-
lute dense area (β = 0.161, 95% CI = −0.236, 0.556) and percentage dense area (β = 0.162, 
95% CI = −0.210, 0.534) among relatives compared to controls. However, the evidence was 
weak. 
Figures 1 and 2 show the estimated marginal means for case-relative-control status 
for each MBD measure across both studies. The estimated marginal mean of each MBD 
measure increases as the status changes from control to relative to case in both studies. 
However, the confidence intervals are overlapping. 
 
Figure 1. Estimated marginal means for dense area (a) and percentage dense area (b) adjusted for age, BMI, time be-
tween BMI measurement and mammogram and the GRM by case, relative and control status for kConFab sample. 
Figure 1. Estimated marginal means for dense area (a) and percentage dense area (b) adjusted for
age, BMI, time betw e BMI measurement and mammogram and the GRM by case, relative and
control status for kConFab sample.
Cancers 2021, 13, x FOR PEER REVIEW 8 of 11 
 
 
Figure 2. Estimated marginal means for dense area (a) and percentage dense area (b) adjusted for age, BMI, time between 
BMI measurement and mammogram, number of live births, menopause status, and the GRM by case, relative and control 
status for Busselton Health Study sample. 
4. Discussion 
We have systematically assessed, for the first time, whether breast density is an en-
dophenotype for breast cancer using five endophenotype criteria. The results of this study 
show that mammographic breast density (absolute and percent dense area measures) 
meets most of the criteria for being an endophenotype for breast cancer. Using two inde-
pendent samples with a combined sample size of 1910, we provide evidence that (i) MBD 
is associated with breast cancer, (ii) MBD measures are heritable, (iii) within families, 
MBD and breast cancer co-segregate, and (iv) MBD measures within relatives of breast 
cancer cases are higher than in the general population. 
4.1. Criteria 1: MBD Is Associated with Breast Cancer Risk 
We found that both MBD—dense area and percent dense area—were positively as-
sociated with breast cancer risk, independent of age and BMI. These findings replicate 
well-established knowledge that MBD is an independent risk factor for breast cancer risk 
[4,5], and our estimates are consistent with earlier studies investigating per unit increases 
in absolute and percent dense area [23,24]. 
4.2. Criteria 2: MBD Is Heritable 
Consistent with the literature, we estimated the heritability of dense area and percent 
dense area to be 0.59 and 0.68, respectively, within the kConFab study. We have previ-
ously reported heritability estimates between 0.6 and 0.67 for percent dense area [6] and 
0.65 for absolute dense area [7] within Australian and North American twin studies. The 
heritability estimates within the BHS were smaller (h2 = 0.39, h2 = 0.30, respectively). Her-
itability estimates within kConFab were calculated using known familial relationships, 
Figure 2. Estimated marginal means for dense area (a) and percentage dense area (b) adjusted for
ag , BMI, time between BMI measurement and m mmogr m, number of liv births, m nopause
status, and the GRM by case, relative and control status for Busselton Health Study sample.
Cancers 2021, 13, 3916 8 of 11
4. Discussion
We have systematically assessed, for the first time, whether breast density is an
endophenotype for breast cancer using five endophenotype criteria. The results of this
study show that mammographic breast density (absolute and percent dense area measures)
meets most of the criteria for being an endophenotype for breast cancer. Using two
independent samples with a combined sample size of 1910, we provide evidence that (i)
MBD is associated with breast cancer, (ii) MBD measures are heritable, (iii) within families,
MBD and breast cancer co-segregate, and (iv) MBD measures within relatives of breast
cancer cases are higher than in the general population.
4.1. Criteria 1: MBD Is Associated with Breast Cancer Risk
We found that both MBD—dense area and percent dense area—were positively as-
sociated with breast cancer risk, independent of age and BMI. These findings replicate
well-established knowledge that MBD is an independent risk factor for breast cancer
risk [4,5], and our estimates are consistent with earlier studies investigating per unit
increases in absolute and percent dense area [23,24].
4.2. Criteria 2: MBD Is Heritable
Consistent with the literature, we estimated the heritability of dense area and percent
dense area to be 0.59 and 0.68, respectively, within the kConFab study. We have previously
reported heritability estimates between 0.6 and 0.67 for percent dense area [6] and 0.65
for absolute dense area [7] within Australian and North American twin studies. The
heritability estimates within the BHS were smaller (h2 = 0.39, h2 = 0.30, respectively).
Heritability estimates within kConFab were calculated using known familial relationships,
while estimates within the BHS were calculated using the SNP-based relatedness estimates
(and therefore represent the variation due only to the SNPs). The lower estimates within
the BHS compared to kConFab are therefore likely due to the fact that total heritability
(due to all genetic variation) is assessed in the kConFab, whereas in the BHS the heritability
estimate only reflects genetic variation captured by SNPs.
4.3. Criteria 3 and 4: Breast Cancer Segregates with Breast Density within Families, and
Non-Affected Family Members Have an Intermediate (between Cases and Unrelated Controls)
Breast Density
In our meta-analysis between the kConFab and BHS studies, we identified higher
breast density in breast cancer cases, intermediate density in relatives of cases, and lower
density in controls for both MBD measures. Evidence for these differences was strong
comparing cases and relatives but was limited when comparing the relatives and controls.
As the relatives of cases within the kConFab study may be more likely to have genetic
variants predisposing them to breast cancer, the estimates involving relatives may be
subject to selection bias. The differences in estimates involving relatives between kConFab
and BHS might be due to both breast cancer and MBD having a greater genetic contribution
(and lower environmental contribution) in the kConFab sample. The pooled marginal
mean estimates were not significantly different (potentially due to lack of power), but did
show an increase across each category, in line with cases having higher density, relatives
with intermediate density and controls with the lowest density. These associations suggest
that there is a genetic component in common between breast cancer and MBD measures.
This study has a number of strengths. First, we had access to genetic, mammography,
and breast cancer case status from two epidemiological studies, representing 1910 women,
consisting of 180 cases, 251 relatives of cases, and 1479 controls. The addition of family
members within these studies allowed us to test the criteria among relatives of controls
which is often not available in population-based or case–control cohorts. Second, the use of
two studies also allowed us to validate our findings in an independent cohort, which is
integral to genetic studies of this type. Third, we assessed the endophenotype criteria using
two measures of MBD, percent and absolute dense area, and observed consistent results
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for both phenotypes. This is consistent with strong genetic correlation between percent
and absolute dense area (kConFab: rhoG = 0.938, p-value = 0.008 and BHS: rhoG = 0.946,
p-value < 0.001).
However, this study has some limitations. First, we did not have BRCA1/2 status for
the BHS, and therefore were unable to exclude these women. However, the prevalence
of these mutations in a population-based cohort is low (<1%; [25]), and therefore the
proportion of women with these mutations in our population-based study would be small.
Second, our study samples consisted mainly of women with European ancestry, and
therefore our results may not be generalisable to other ethnic groups. However, previous
studies have shown that MBD measures are strongly associated with breast cancer risk
across different ethnic groups [26,27]. Finally, BMI measures for some participants were
not available, and as BMI is a critical MDB covariate, these participants had to be excluded
from analyses.
5. Conclusions
In summary, we have shown through a comprehensive assessment of endophenotype
criteria that two measures of breast density—dense area and percent dense area—are
endophenotypes for breast cancer. As MDB is genetically correlated with breast cancer and
can be measured on any woman who has had a mammogram (regardless of breast cancer
status), genetic investigations of MDB may potentially identify novel risk variants for
breast cancer and help identify novel breast cancer mechanisms. Improved understanding
of these genetic associations could also inform future research towards tailored screening
programs and prevention strategies.
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